Stock Events

Stock Events

Lineage Cell Therapeutics 

$1.0800
68
-$0.02-1.82% 20:00 Today
+$0.00+0%20:07After hours

Statistics

Day High
1.0991
Day Low
1.04
52W High
2.09
52W Low
1
Volume
1,474,327
Avg. Volume
1,353,966
Mkt Cap
273.14M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.13
-0.09
-0.06
-0.02
Expected EPS
-0.033333
Actual EPS
N/A

Financials

-436.47%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
14.56MRevenue
-63.53MNet Income

Analyst Ratings

6.25Average Price Target
The highest estimate is 9.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LCTX. It's not an investment recommendation.
Microsoft
14
MSFT
Apple
12
AAPL
NVIDIA
10
NVDA
Meta Platforms
10
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Stem
STEM
Mkt Cap61.03M
StemCells, Inc. focuses on cell-based therapeutics, directly competing in the regenerative medicine space with Lineage Cell Therapeutics.
Biolife Solutions
BLFS
Mkt Cap1.72B
BioLife Solutions, Inc. provides bioproduction tools and services, including cell and gene therapy solutions, indirectly competing with Lineage's operational needs.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics AG focuses on gene editing, a technology that could potentially compete with or complement Lineage's cell therapy approaches.
Editas Medicine
EDIT
Mkt Cap433.1M
Editas Medicine, Inc. is involved in gene editing, representing a competitive or complementary approach to Lineage's cell-based therapies.
Vericel
VCEL
Mkt Cap2.26B
Vericel Corporation focuses on autologous cell therapies for the treatment of patients with serious diseases, directly competing in the regenerative medicine sector.
Mesoblast
MESO
Mkt Cap2.02B
Mesoblast Limited specializes in regenerative medicine, developing mesenchymal lineage adult stem cell therapies, closely competing with Lineage's therapeutic approaches.
Fate Therapeutics
FATE
Mkt Cap307.94M
Fate Therapeutics, Inc. is dedicated to the development of programmed cellular immunotherapies, competing in the broader cell therapy market.

About

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Show more...
CEO
Brian Culley
Employees
77
Country
United States
ISIN
US53566P1093
WKN
000A2PP89

Listings

STU
DE
BT3.STU
XASE
US
LCTX
F
DE
BT3.F
BOATS
BOATS
LCTX.BOATS

0 Comments

Share your thoughts

FAQ

What is Lineage Cell Therapeutics stock price today?▼
The current price of LCTX is $1.08 USD — it has decreased by -1.82% in the past 24 hours. Watch Lineage Cell Therapeutics stock price performance more closely on the chart.
What is Lineage Cell Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XASE exchange Lineage Cell Therapeutics stocks are traded under the ticker LCTX.
Is Lineage Cell Therapeutics stock price growing?▼
LCTX stock has risen by +1.89% compared to the previous week, the month change is a -1.82% fall, over the last year Lineage Cell Therapeutics has showed a -9.24% decrease.
What is Lineage Cell Therapeutics market cap?▼
Today Lineage Cell Therapeutics has the market capitalization of 273.14M
When is the next Lineage Cell Therapeutics earnings date?▼
Lineage Cell Therapeutics is going to release the next earnings report on November 05, 2026.
What were Lineage Cell Therapeutics earnings last quarter?▼
LCTX earnings for the last quarter are -0.03 USD per share, whereas the estimation was -0.03 USD resulting in a -5.88% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Lineage Cell Therapeutics revenue for the last year?▼
Lineage Cell Therapeutics revenue for the last year amounts to 14.56M USD.
What is Lineage Cell Therapeutics net income for the last year?▼
LCTX net income for the last year is -63.53M USD.
How many employees does Lineage Cell Therapeutics have?▼
As of August 20, 2026, the company has 77 employees.
In which sector is Lineage Cell Therapeutics located?▼
Lineage Cell Therapeutics operates in the Health & Wellness sector.
When did Lineage Cell Therapeutics complete a stock split?▼
Lineage Cell Therapeutics has not had any recent stock splits.
Where is Lineage Cell Therapeutics headquartered?▼
Lineage Cell Therapeutics is headquartered in CARLSBAD, United States.